Regeneron CEO Dr. Leonard Schleifer discusses his company’s approach in treating the coronavirus.
PARIS - U.S. company Regeneron Pharmaceuticals said it had agreed to repurchase approximately $5 billion of its shares directly from French drugmaker Sanofi.
|REGN||REGENERON PHARMACEUTICALS INC.||620.86||-19.77||-3.09%|
REGENERON SAYS COVID-19 ANTIBODY COCKTAIL MAY BE AVAILABLE BY FALL
Sanofi, which holds about 23.2 million Regeneron shares, said separately it intended to sell its equity investment, and that the move would not change ongoing collaboration between the two groups.
GET FOX BUSINESS ON THE GO BY CLICKING HERE